Tessa Visits: Ulcerative Colitis: Optimizing Treatment Strategies to Improve Patient Outcomes

Ulcerative Colitis: Optimizing Treatment Strategies to Improve Patient Outcomes
1 AMA PRA Category 1 Credit(s)
Launch Date:
October 24, 2013
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

physicians who manage patients with ulcerative colitis (UC)

Relevant Terms:

Ulcerative Colitis, IBD, Non-Responsive UC, Refractory UC, Long-term Therapy, Remission

William J. Sandborn, MD, Program Chair  

William J. Sandborn, MD - Program Chair 
Chief, Division of Gastroenterology
Professor of Medicine
UC San Diego School of Medicine
San Diego, CA

Dr. William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda, California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester, Minnesota, in 1993. Dr. Sandborn was on the faculty of the Mayo Clinic from 1993 to 2010, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011 he became Professor of Clinical Medicine at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System. Dr. Sandborn has published over 443 peer-reviewed articles including articles in the New England Journal of Medicine, Lancet, JAMAAnnals of Internal Medicine, and Gastroenterology. His research interests are clinical trials and clinical pharmacology related to inflammatory bowel disease.

Marla C. Dubinsky, MD

Marla C. Dubinsky, MD
Director, Pediatric Inflammatory Bowel Disease Program
Abe and Claire Levine Chair in Pediatric Inflammatory
Bowel Disease
Associate Professor of Pediatrics
Cedars-Sinai Medical Center
Los Angeles, CA

Marla C. Dubinsky, MD, is Director of the Pediatric Inflammatory Bowel Disease Program and Associate Professor of Pediatrics at Cedars-Sinai Medical Center. She holds the Abe and Claire Levine Chair in Pediatric Inflammatory Bowel Disease.
Dr. Dubinsky's research interests include the immune and genetic influences on the natural history and treatment of inflammatory bowel disease (IBD) as well as therapeutic drug monitoring.  Her research is funded by the National Institutes of Health.

Dr. Dubinsky has lectured internationally and has also authored book chapters for Trends in Inflammatory Bowel Disease Therapy and Inflammatory Bowel Disease: Diagnosis and Therapeutics. She has also written articles for numerous peer-reviewed journals including Gastroenterology, Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and American Journal of Gastroenterology.

David T. Rubin, MD

David T. Rubin, MD
Professor of Medicine
Co-Director, Inflammatory Bowel Disease Center
Associate Section Chief, Education
Section of Gastroenterology, Hepatology and Nutrition
University of Chicago Medicine
Chicago, Illinois

David T. Rubin earned a medical degree with honors from the University Of Chicago Pritzker School Of Medicine. He completed his residency in internal medicine and both of his fellowships in gastroenterology and clinical medical ethics at the University of Chicago, where he served as Chief Resident and Chief Fellow. In addition to his positions with the University of Chicago Medical Center, Dr. Rubin is also an associate faculty member at the MacLean Center for Clinical Medical Ethics and an associate investigator at the UC Comprehensive Cancer Center.
Dr. Rubin is a Fellow of the American Gastroenterological Association, the American College of Gastroenterology (ACG), and American College of Physicians and an active national member of the Crohn's and Colitis Foundation of America. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America's Top Physicians (gastroenterology). Additionally, he received the ACG's Governor's Award of Excellence in Clinical Research (2003), the Cancer Research Foundation Young Investigator's Award (2004), and the UC Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the CCFA's Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families.
Dr. Rubin is the editor of a best-selling book on inflammatory bowel disease (IBD) and an author or coauthor of many peer-reviewed articles on IBD, virtual colonoscopy, genetic testing in IBD, and cancer in IBD. He is also a featured media contact for issues related to IBD, appearing on satellite radio, television and print media. His principal research interests include novel IBD therapies and outcomes, colon cancer prevention, and clinical medical ethics.
1. Describe the efficacy and safety data for existing, new and emerging treatments for UC
2. Appropriately select treatments for patients with UC that maximize the opportunity to achieve remission, avoid relapse and minimize complications in accordance with existing guidelines
3. Implement evidence-based strategies to improve management of therapeutic non-response or refractoriness in UC

Accreditation Statement and Credit Designation
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.                                               
The AGA Institute designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
How to Receive Credit
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA Category 1 Credit(s)™. You must complete the post-test and evaluation in order to receive credit for this activity. 
All other participants who successfully complete the post-test and evaluation will receive a certificate of completion.
A statement of credit will be e-mailed to you and will also be available to print from your user history page. 
Disclosure of Conflicts of Interest
In accordance with the ACCME's Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
Faculty Disclosures
Dr. Sandborn has received consulting fees from Janssen, Abbott Laboratories (now AbbVie), UCB Pharma, Salix, Shire, Warner Chilcott, Prometheus Laboratories, Santarus, Bristol-Myers Squibb, Genentech, Amgen, Pfizer, Receptos, GlaxoSmithKline, and Millennium (a Takeda company).
Dr. Sandborn also serves on the Speakers Bureau for AbbVie, and has received research grants from Janssen, Bristol-Myers Squibb, Genentech, Amgen, Pfizer, Receptos and GlaxoSmithKline.
Dr. Dubinsky has served as a consultant for Janssen, Pfizer, Bristol-Myers Squibb, UCB, Abbott, Shire, Prometheus, and Takeda, and has received a research grant from Janssen.
Dr. Rubin serves as a consultant for Prometheus Pharmaceuticals, AbbVie (Abbott Immunology), UCB Pharma, Centocor/Janssen, Elan Pharmaceuticals, Takeda-Millennium, Given Imaging, Bristol-Meyers Squibb, Ironwood, Lifecore Biomedical, LLC, Emmi, Telsar Pharmaceuticals, Vertex Pharmaceuticals, and Santarus.
Dr. Rubin has also received grants or research support from Warner Chilcott, Prometheus Pharmaceuticals, AbbVie (Abbott Immunology) (Registry), Shire, and Elan Pharmaceuticals (Registry).
Additionally, Dr. Rubin is co-founder of Cornerstones Health, Inc., a non-profit medical education entity.
RMEI Disclosures
Program planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose. 
Cynthia M. Kunzer, CMP, has no affiliations with commercial interests to disclose.

AGA Planning Committee
AGA Staff and all other individuals with the planning and delivering the content disclosed no relevant financial relationships.
General Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.
Commercial Support
This is a program of the AGA in collaboration with RMEI, LLC. RMEI gratefully acknowledges an educational grant from Takeda Pharmaceuticals North America, Inc. in support of this CME activity.
Fee Information
There is no fee for this educational activity.
Supported Browsers
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 18.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
Safari 4.0+ for Mac OSX 10.5 and above

Supported Phones/Tablets
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above